Association between rs1800795 polymorphism in the interleukin-6 gene and the risk of polycystic ovary syndrome

Abstract

Objective:Several published articles have investigated the association between the −174 G/C (rs1800795) polymorphism in the interleukin-6 (IL-6) gene and the risk of polycystic ovary syndrome (PCOS). However, the results were inconsistent. In the present study, a meta-analysis was performed to resolve this inconsistency.Methods:Eligible studies reporting an association between the IL-6 rs1800795 polymorphism and PCOS susceptibility were included from PubMed, Embase, Web of Science, and the Cochrane Library up to December 1, 2017. The odds ratio (OR) with the 95% confidence interval (CI) was used to calculate the strength of the associations. Publication bias detection was conducted using Begg test. We used STATA 11.0 software to perform the statistical analyses.Results:Six articles detailing case-control studies were included, reporting a total of 512 cases and 606 controls. The meta-analysis results indicated that rs1800795 was associated with decreased PCOS susceptibility in the overall population under the allelic model (G vs. C, OR = 0.59, 95% CI: 0.41–0.85, P = .005), the homozygous model (GG vs. CC, OR = 0.45, 95% CI: 0.28–0.73, P = .001), heterozygous model (GG vs. CG, OR = 0.50, 95% CI: 0.26–0.95, P = .036), and the dominant model (GC + CC vs. GG, OR = 0.48, 95% CI: 0.26–0.89, P = .020). However, a threshold P value of .05 was found under the recessive model (CC vs. GG + CG, OR = 0.62, 95% CI: 0.39–1.00).Conclusions:This meta-analysis concluded that IL-6 rs1800795 polymorphism has a decreased association with PCOS risk among all populations studied. The results suggested that the IL-6 rs1800795 polymorphism is a protective factor for PCOS susceptibility. Given the limited ethnic groups and sample size, further studies are required to validate the association.

The Genetics of Polycystic Ovary Syndrome: An Overview of Candidate Gene Systematic Reviews and Genome-Wide Association Studies

“…All 21 systematic reviews included a meta-analysis and were based on case-control or cross-sectional primary studies. Nineteen systematic reviews investigated SNPs [33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51]. The remaining two systematic reviews investigated CAG repeat length or tandem repeats respectively [52,53].…”

“…The remaining two systematic reviews investigated CAG repeat length or tandem repeats respectively [52,53]. Candidate genes focused on three main aspects of PCOS pathophysiology: metabolic dysfunction, [33,35,38,39,40,41,42,43,44,48,49,50,52], imbalances in androgens and gonadotrophins [36,37,51,53], and inflammation [34,45,46,47].…”

Interleukin-6 -174 G/C polymorphism is associated with the risk of basal cell carcinoma in a Chinese Han population

“…The meta-analysis from Zhou et al revealed a non-significant association between the IL-6 -174 G/C polymorphism and overall cancer risk [ 17 ]. On the other hand, Chen et al found that the IL-6 -174 G/C polymorphism protected against polycystic ovary syndrome [ 18 ]. And Duan et al reported that the -174 G/C polymorphism was a low-penetrance susceptibility variant for cervical cancer [ 19 ].…”

The association between Interleukin-6 rs1800795/rs1800797 polymorphisms and risk of rotator cuff tear in a Chinese population

“…The association between IL-6 rs1800795 polymorphism and disease risk such as cervical cancer [18]; polycystic ovary syndrome [19]; type 2 diabetes [20] and rheumatoid arthritis [21], has been widely investigated. Similarly, IL-6 rs1800797 polymorphism has also been studied in various disease [22][23][24][25].…”